Alogliptin, known as alogliptin benzoate, is commonly available in capsule and tablet form as a type of oral hypoglycemic drug. It is mainly used for the treatment of type 2 diabetes mellitus, and usually takes effect about 30 minutes after administration, and the effect can be maintained for about 24 hours. Alogliptin can be used as monotherapy or in combination with metformin to improve glycemic control in patients with type 2 diabetes on the basis of diet and exercise, and should be avoided in patients with type 1 diabetes or diabetic ketoacidosis. There are some contraindications to the use of alogliptin that should be taken into account, and it is contraindicated in patients with a history of severe hypersensitivity reactions to alogliptin-containing products, such as anaphylactic reactions, angioedema, or severe adverse skin reactions. Possible adverse reactions to the drug are pancreatitis, allergic reactions, hypoglycemia. Please regulate the use of the drug in strict accordance with medical advice to avoid adverse effects. Promptly seek medical attention in case of discomfort.